IDEAS home Printed from https://ideas.repec.org/a/bla/glopol/v12y2021is6p12-20.html

21st Century Capitalism and Innovation for Health

Author

Listed:
  • Susan K. Sell

Abstract

21st century capitalism undermines health outcomes in myriad ways. Structural economic changes have had negative effects on medical innovation and public health and are poorly aligned with social goals. Key features of the contemporary political economy include both monopoly capitalism, based upon stringent intellectual (IP) protection that suppresses economic competition, and Wall Street capitalism, or financialization, that prioritizes value extraction over value creation to maximize shareholder value. Contemporary trends in the pharmaceutical and medical device industries, digital health, and regulatory change demonstrate some of the negative impacts of 21st century capitalism on public health.

Suggested Citation

  • Susan K. Sell, 2021. "21st Century Capitalism and Innovation for Health," Global Policy, London School of Economics and Political Science, vol. 12(S6), pages 12-20, July.
    • Handle: RePEc:bla:glopol:v:12:y:2021:i:s6:p:12-20
    DOI: 10.1111/1758-5899.12911
    as

    Download full text from publisher

    File URL: https://doi.org/10.1111/1758-5899.12911
    Download Restriction: no
    File URL: https://libkey.io/10.1111/1758-5899.12911?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Schwartz, Herman Mark, 2017. "Club goods, intellectual property rights, and profitability in the information economy†," Business and Politics, Cambridge University Press, vol. 19(2), pages 191-214, June.
    2. Sell,Susan K., 2003. "Private Power, Public Law," Cambridge Books, Cambridge University Press, number 9780521819145.
    3. Mariana Mazzucato & Victor Roy, 2019. "Rethinking value in health innovation: from mystifications towards prescriptions," Journal of Economic Policy Reform, Taylor & Francis Journals, vol. 22(2), pages 101-119, April.
    4. P. Lehoux & F. A. Miller & G. Daudelin & D. R. Urbach, 2016. "How venture capitalists decide which new medical technologies come to exist," Science and Public Policy, Oxford University Press, vol. 43(3), pages 375-385.
    5. Pascale Lehoux & Hudson Pacifico Silva & Renata Pozelli Sabio & Federico Roncarolo, 2018. "The Unexplored Contribution of Responsible Innovation in Health to Sustainable Development Goals," Sustainability, MDPI, vol. 10(11), pages 1-21, November.
    6. Ugo Pagano, 2014. "The crisis of intellectual monopoly capitalism," Cambridge Journal of Economics, Cambridge Political Economy Society, vol. 38(6), pages 1409-1429.
    7. Öner Tulum & William Lazonick, 2018. "Financialized Corporations in a National Innovation System: The U.S. Pharmaceutical Industry," International Journal of Political Economy, Taylor & Francis Journals, vol. 47(3-4), pages 281-316, October.
    8. Benjamin M. Hunter & Susan F. Murray, 2019. "Deconstructing the Financialization of Healthcare," Development and Change, International Institute of Social Studies, vol. 50(5), pages 1263-1287, September.
    9. Mariana Mazzucato & Victor Roy, 2019. "Rethinking value in health innovation: from mystifications towards prescriptions," Journal of Economic Policy Reform, Taylor and Francis Journals, vol. 22(2), pages 101-119, April.
    10. Lehoux, P. & Daudelin, G. & Williams-Jones, B. & Denis, J.-L. & Longo, C., 2014. "How do business model and health technology design influence each other? Insights from a longitudinal case study of three academic spin-offs," Research Policy, Elsevier, vol. 43(6), pages 1025-1038.
    11. Lehoux, P. & Miller, F.A. & Daudelin, G., 2017. "Converting clinical risks into economic value: The role of expectations and institutions in health technology development," Technological Forecasting and Social Change, Elsevier, vol. 117(C), pages 206-216.
    12. Gleadle, Pauline & Parris, Stuart & Shipman, Alan & Simonetti, Roberto, 2014. "Restructuring and innovation in pharmaceuticals and biotechs: The impact of financialisation," CRITICAL PERSPECTIVES ON ACCOUNTING, Elsevier, vol. 25(1), pages 67-77.
    13. Sell,Susan K., 2003. "Private Power, Public Law," Cambridge Books, Cambridge University Press, number 9780521525398.
    14. Busfield, Joan, 2020. "Documenting the financialisation of the pharmaceutical industry," Social Science & Medicine, Elsevier, vol. 258(C).
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Walter G. Johnson, 2023. "Caught in quicksand? Compliance and legitimacy challenges in using regulatory sandboxes to manage emerging technologies," Regulation & Governance, John Wiley & Sons, vol. 17(3), pages 709-725, July.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Susan K. Sell, 2020. "What COVID-19 Reveals About Twenty-First Century Capitalism: Adversity and Opportunity," Development, Palgrave Macmillan;Society for International Deveopment, vol. 63(2), pages 150-156, December.
    2. Tristan Auvray & Cédric Durand & Joel Rabinovich & Cecilia Rikap, 2020. "Financialization's conservation and transformation: from Mark I to Mark II," Working Papers hal-03079425, HAL.
    3. Tristan Auvray & Cédric Durand & Joel Rabinovich & Cecilia Rikap, 2021. "Corporate financialization’s conservation and transformation: from Mark I to Mark II," Review of Evolutionary Political Economy, Springer, vol. 2(3), pages 431-457, December.
    4. repec:hal:cepnwp:hal-03079425 is not listed on IDEAS
    5. Walsh, P.P. & Murphy, E. & Horan, D., 2020. "The role of science, technology and innovation in the UN 2030 agenda," Technological Forecasting and Social Change, Elsevier, vol. 154(C).
    6. Mohammad Yamin, 2011. "A Commentary on Peter Buckley’s Writings on the Global Factory," Management International Review, Springer, vol. 51(2), pages 285-293, April.
    7. Flynn, Matthew B., 2021. "Global capitalism as a societal determinant of health: A conceptual framework," Social Science & Medicine, Elsevier, vol. 268(C).
    8. Blandine Laperche, 2008. "Stratégies d’innovation des firmes des sciences de la vie et appropriation des ressources végétales : processus et enjeux Innovations strategies of firms in life science and appropriation of vegetal resources : process and stakes," Working Papers 189, Laboratoire de Recherche sur l'Industrie et l'Innovation. ULCO / Research Unit on Industry and Innovation.
    9. Amandine Bled, 2009. "Business to the rescue: private sector actors and global environmental regimes’ legitimacy," International Environmental Agreements: Politics, Law and Economics, Springer, vol. 9(2), pages 153-171, May.
    10. Jandhyala, Srividya, 2015. "International and domestic dynamics of intellectual property protection," Journal of World Business, Elsevier, vol. 50(2), pages 284-293.
    11. David Clayton, 2011. "Trade‐Offs And Rip‐Offs: Imitation‐Led Industrialisation And The Evolution Of Trademark Law In Hong Kong," Australian Economic History Review, Economic History Society of Australia and New Zealand, vol. 51(2), pages 178-198, July.
    12. Gleeson, Deborah & Lexchin, Joel & Labonté, Ronald & Townsend, Belinda & Gagnon, Marc-André & Kohler, Jillian & Forman, Lisa & Shadlen, Kenneth C., 2019. "Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts," LSE Research Online Documents on Economics 103027, London School of Economics and Political Science, LSE Library.
    13. Christopher May, 2006. "Escaping the TRIPs’ Trap: The Political Economy of Free and Open Source Software in Africa," Political Studies, Political Studies Association, vol. 54(1), pages 123-146, March.
    14. Bayer, Patrick & Marcoux, Christopher & Urpelainen, Johannes, 2013. "Leveraging private capital for climate mitigation: Evidence from the Clean Development Mechanism," Ecological Economics, Elsevier, vol. 96(C), pages 14-24.
    15. Mohammed El Said, 2020. "Radical Approaches During Unusual Circumstances: Intellectual Property Regulation and the COVID-19 Dilemma," Development, Palgrave Macmillan;Society for International Deveopment, vol. 63(2), pages 209-218, December.
    16. Rawi Abdelal, 2010. "The Profits of Power: Commercial Realpolitik in Europe and Eurasia," Harvard Business School Working Papers 11-028, Harvard Business School, revised Mar 2011.
    17. Archibugi, Daniele & Filippetti, Andrea, 2010. "The globalisation of intellectual property rights: four learned lessons and four theses," MPRA Paper 21930, University Library of Munich, Germany.
    18. Gjølberg Maria, 2011. "Explaining Regulatory Preferences: CSR, Soft Law, or Hard Law? Insights from a Survey of Nordic Pioneers in CSR," Business and Politics, De Gruyter, vol. 13(2), pages 1-33, August.
    19. Anne Roemer-Mahler, 2013. "Business conflict and global politics: The pharmaceutical industry and the global protection of intellectual property rights," Review of International Political Economy, Taylor & Francis Journals, vol. 20(1), pages 121-152, February.
    20. Singh, J.P. & Flyverbom, Mikkel, 2016. "Representing participation in ICT4D projects," Telecommunications Policy, Elsevier, vol. 40(7), pages 692-703.
    21. Emilie Cloatre & Robert Dingwall, 2013. "“Embedded regulation:” The migration of objects, scripts, and governance," Regulation & Governance, John Wiley & Sons, vol. 7(3), pages 365-386, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:glopol:v:12:y:2021:i:s6:p:12-20. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: https://edirc.repec.org/data/lsepsuk.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.